Weight has emerged as a principal screening and monitoring indicator in post-acute and long-term care (PALTC) because it is easy to measure and the measurement is reasonably accurate and reproducible, noninvasive, acceptable to most patients, and relatively inexpensive to obtain. Among patients who remain ...
Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.